All companies

Every company, every area

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Unlock with Research ↗

Research

Compare company financial metrics

Research adds sourced market cap, cash, runway and annualized R&D figures with metric-specific sorting.

← browse by therapeutic area

Every company, every area

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Views

1287 of 1287 companies

Company	Pipeline	Most advanced	Next readout
AstraZenecaAZN · Nasdaq	78 assets: 28 approved, 21 Ph 3, 19 Ph 2, 10 Ph 1	AZD0780Phase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal	19 Oct 2026Benralizumab · Approved
PfizerPFE · NYSE	76 assets: 41 approved, 11 Ph 3, 14 Ph 2, 10 Ph 1	TavapadonPhase 3 · Parkinson's DiseaseReliable signal	9 Oct 2026Sasanlimab · Phase 1
Eli LillyLLY · NYSE	68 assets: 28 approved, 13 Ph 3, 12 Ph 2, 14 Ph 1, 1 other	eloralintidePhase 3 · ObesityReliable signal	Nov 2026tirzepatide · Phase 3
GlaxoSmithKlineGSK · NYSE	59 assets: 27 approved, 15 Ph 3, 12 Ph 2, 4 Ph 1, 1 other	fluticasone propionate/salmeterolPhase 3 · AsthmaReliable signal	13 Oct 2026Dostarlimab · Phase 1/2
AbbVieABBV · NYSE	57 assets: 19 approved, 10 Ph 3, 13 Ph 2, 14 Ph 1, 1 other	TavapadonPhase 3 · Parkinson's DiseaseReliable signal	Nov 2026Budigalimab · Phase 2
NovartisNVS · NYSE	57 assets: 29 approved, 9 Ph 3, 10 Ph 2, 9 Ph 1	indacaterol maleate / mometasone furoatePhase 3 · AsthmaReliable signal	5 Oct 2026Capmatinib · Phase 1
Jiangsu Hengrui Pharmaceuticals600276 · SSE	56 assets: 27 Ph 3, 16 Ph 2, 13 Ph 1	ApatinibPhase 3 · Non-Small Cell Lung CancerReliable signal	30 Oct 2026HRS-6209 · Phase 1/2
Bristol-Myers SquibbBMY · NYSE	49 assets: 20 approved, 10 Ph 3, 11 Ph 2, 8 Ph 1	AzacitidinePhase 3 · Acute Myeloid LeukemiaPartial signal	5 Oct 2026Xanomeline/trospium chloride · Phase 3
Johnson & JohnsonJNJ · NYSE	49 assets: 32 approved, 7 Ph 3, 7 Ph 2, 3 Ph 1	SeltorexantPhase 3 · Major Depressive DisorderReliable signal	30 Oct 2026bleximenib · Phase 1
RocheRHHBY · OTC	49 assets: 21 approved, 14 Ph 3, 9 Ph 2, 5 Ph 1	astegolimabPhase 3 · Chronic Obstructive Pulmonary DiseaseReliable signal	8 Oct 2026RO7247669 · Phase 2
Boehringer IngelheimPrivate	39 assets: 14 approved, 10 Ph 3, 9 Ph 2, 6 Ph 1	fenoterol/ipratropium bromidePhase 3 · AsthmaReliable signal	6 Oct 2026BI 3000202 · Phase 1
SanofiSNY · Nasdaq	37 assets: 14 approved, 7 Ph 3, 10 Ph 2, 6 Ph 1	Ciclesonide (XRP1526)Phase 3 · AsthmaReliable signal	7 Oct 2026dupilumab · Phase 3
Merck & Co.MRK · NYSE	34 assets: 12 approved, 14 Ph 3, 5 Ph 2, 3 Ph 1	EnlicitidePhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal	9 Oct 2026Alimatravir · Phase 1
AmgenAMGN · Nasdaq	31 assets: 19 approved, 8 Ph 3, 1 Ph 2, 3 Ph 1	ABP 938Phase 3 · Age-Related Macular DegenerationReliable signal	31 Oct 2026Sotorasib · Phase 1
Regeneron PharmaceuticalsREGN · Nasdaq	31 assets: 6 approved, 8 Ph 3, 14 Ph 2, 3 Ph 1	itepekimabPhase 3 · Chronic Obstructive Pulmonary DiseaseReliable signal	7 Oct 2026dupilumab · Phase 3
Novo NordiskNVO · NYSE	28 assets: 9 approved, 8 Ph 3, 5 Ph 2, 6 Ph 1	amycretinPhase 3 · ObesityReliable signal	Dec 2026UBT251 · Phase 1
Gilead SciencesGILD · Nasdaq	20 assets: 9 approved, 6 Ph 3, 4 Ph 2, 1 Ph 1	AmbrisentanPhase 3 · HypertensionReliable signal	Dec 2026Sacituzumab Govitecan · Phase 3
Qilu PharmaceuticalPrivate	18 assets: 10 Ph 3, 6 Ph 2, 2 Ph 1	QLM3003Phase 3 · Atopic DermatitisPartial signal	31 Oct 2026QL1706 · Phase 2
Takeda Pharmaceutical CompanyTAK · NYSE	18 assets: 8 approved, 9 Ph 3, 1 Ph 2	zasocitinibPhase 3 · Psoriatic ArthritisReliable signal	17 Feb 2027zasocitinib · Phase 2
BiogenBIIB · Nasdaq	17 assets: 9 approved, 3 Ph 3, 4 Ph 2, 1 Ph 1	LitifilimabPhase 3 · Systemic Lupus ErythematosusReliable signal	20 Oct 2026Litifilimab · Phase 2/3
Ionis PharmaceuticalsIONS · Nasdaq	17 assets: 6 approved, 5 Ph 3, 5 Ph 2, 1 Ph 1	PelacarsenPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal	Dec 2026Donidalorsen · Phase 3
Arrowhead PharmaceuticalsARWR · Nasdaq	16 assets: 1 approved, 3 Ph 3, 9 Ph 2, 3 Ph 1	OlpasiranPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal	Dec 2026SRP-1004 · Phase 1
UCBUCBJY · OTC	16 assets: 9 approved, 1 Ph 3, 3 Ph 2, 3 Ph 1	Staccato AlprazolamPhase 3 · EpilepsyReliable signal	31 Oct 2026Staccato Alprazolam · Phase 3
Vertex PharmaceuticalsVRTX · Nasdaq	16 assets: 7 approved, 3 Ph 3, 5 Ph 2, 1 Ph 1	PovetaciceptPhase 3 · Myasthenia Gravis	30 Oct 2026Vanzacaftor / tezacaftor / deutivacaftor · Phase 3
BayerBAYN · Xetra	15 assets: 5 approved, 5 Ph 3, 3 Ph 2, 2 Ph 1	RiociguatPhase 3 · HypertensionReliable signal	7 Oct 2026BAY3283142 · Phase 1
Hansoh Pharmaceutical Group3692 · HKEX	15 assets: 8 Ph 3, 4 Ph 2, 3 Ph 1	HS-20094Phase 3 · ObesityReliable signal	30 Oct 2026HS-20118 · Phase 1
Alnylam PharmaceuticalsALNY · Nasdaq	14 assets: 6 approved, 4 Ph 3, 3 Ph 2, 1 Ph 1	ZilebesiranPhase 3 · HypertensionReliable signal	12 Oct 2026Cemdisiran · Phase 3
Bausch HealthBHC · NYSE	14 assets: 13 approved, 1 Ph 2	amiselimodPhase 2 · Ulcerative ColitisReliable signal	Dec 2028brodalumab · Approved
Celltrion068270 · KOSPI	14 assets: 9 approved, 5 Ph 3	CT-P10Phase 3 · Rheumatoid ArthritisReliable signal	Feb 2027CT-P51 · Phase 3
Innovent Biologics1801 · HKEX	13 assets: 9 Ph 3, 2 Ph 2, 2 Ph 1	IBI305Phase 3 · Non-Small Cell Lung CancerReliable signal	31 Oct 2026IBI3003 · Phase 1/2
Shanghai Henlius Biotech2696 · HKEX	13 assets: 7 Ph 3, 4 Ph 2, 2 Ph 1	HLX01Phase 3 · Rheumatoid ArthritisReliable signal	22 Oct 2026Serplulimab · Phase 2
Sino Biopharmaceutical1177 · HKEX	13 assets: 1 approved, 6 Ph 3, 3 Ph 2, 3 Ph 1	CulmerciclibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal	Dec 2026Culmerciclib · Phase 3
Teva Pharmaceutical IndustriesTEVA · NYSE	13 assets: 9 approved, 3 Ph 3, 1 Ph 1	Olanzapine (TV-44749)Phase 3 · SchizophreniaReliable signal	15 Jan 2027Anle138b · Phase 1
ViiV HealthcarePrivate	13 assets: 6 approved, 5 Ph 2, 2 Ph 1	VH3739937Phase 2 · HIVPartial signal	22 Jan 2027Fostemsavir · Phase 1
Daiichi Sankyo4568 · TSE	12 assets: 3 approved, 5 Ph 3, 3 Ph 2, 1 Ph 1	MirogabalinPhase 3 · Diabetic Peripheral Neuropathic PainReliable signal	20 Oct 2026DS-3939a · Phase 1/2
OrganonOGN · NYSE	12 assets: 7 approved, 4 Ph 3, 1 other	EzetimibePhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal	Aug 2027Tapinarof · Phase 3
Otsuka Holdings4578 · TSE	12 assets: 8 approved, 2 Ph 3, 1 Ph 2, 1 Ph 1	OPC-61815Phase 3 · Heart FailurePartial signal	20 Oct 2026Ulotaront · Phase 3
Akeso9926 · HKEX	11 assets: 7 Ph 3, 4 Ph 2	PenpulimabPhase 3 · Non-Small Cell Lung CancerReliable signal	22 Oct 2026AK138D1 · Phase 1
CSPC Pharmaceutical Group1093 · HKEX	11 assets: 8 Ph 3, 2 Ph 2, 1 other	DBPR108Phase 3 · Type 2 DiabetesReliable signal	10 Oct 2026Ammoxetine · Phase 1
ViatrisVTRS · Nasdaq	11 assets: 10 approved, 1 Ph 3	sildenafilPhase 3 · HypertensionPartial signal	None on record
BioMarin PharmaceuticalBMRN · Nasdaq	10 assets: 7 approved, 2 Ph 3, 1 Ph 2	INZ-701Phase 3 · Chronic Kidney DiseaseWeak signal	14 Oct 2026INZ-701 · Phase 1
H. LundbeckHLUN.B · Nasdaq Copenhagen	10 assets: 7 approved, 2 Ph 3, 1 Ph 2	BexicaserinPhase 3 · EpilepsyPartial signal	31 Oct 2026Bexicaserin · Phase 3
IncyteINCY · Nasdaq	10 assets: 6 approved, 4 Ph 3	INCA033989Phase 3 · Essential Thrombocythemia	9 Oct 2026Ruxolitinib · Phase 3
Amphastar Pharmaceuticals, Inc.AMPH · Nasdaq	9 assets: 8 approved, 1 Ph 3	albuterol sulfate (Amphastar)Phase 3 · AsthmaPartial signal	None on record
Eisai4523 · TSE	9 assets: 5 approved, 3 Ph 3, 1 Ph 2	LemborexantPhase 3 · Alzheimer's DiseasePartial signal	3 Dec 2026Lecanemab · Phase 2
Haisco Pharmaceutical Group002653 · SZSE	9 assets: 5 Ph 3, 1 Ph 2, 2 Ph 1, 1 other	Anrikefon (HSK21542)Phase 3 · Chronic Kidney DiseaseReliable signal	31 Oct 2026HSK44459 · Phase 2
Luye Pharma Group2186 · HKEX	9 assets: 2 approved, 3 Ph 3, 1 Ph 2, 3 Ph 1	Ansofaxine hydrochloridePhase 3 · Major Depressive DisorderReliable signal	28 Feb 2027Ansofaxine hydrochloride · Approved
Sichuan Baili Pharmaceutical688506 · SSE STAR Market	9 assets: 3 Ph 3, 4 Ph 2, 2 Ph 1	BL-B01D1Phase 3 · Non-Small Cell Lung Cancer	Nov 2026BL-B01D1 · Phase 3
Supernus PharmaceuticalsSUPN · Nasdaq	9 assets: 6 approved, 3 Ph 2	SPN-817Phase 2 · EpilepsyWeak signal	30 Dec 2026SPN-817 · Phase 1/2
Yuhan Corporation000100 · KOSPI	9 assets: 1 approved, 3 Ph 3, 2 Ph 2, 3 other	SarpogrelatePhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal	31 Dec 2026Lazertinib · Phase 1
BiocadPrivate	8 assets: 8 Ph 3	AcellbiaPhase 3 · Rheumatoid ArthritisReliable signal	Jul 2028BCD-248 · Phase 3
Jazz PharmaceuticalsJAZZ · Nasdaq	8 assets: 6 approved, 2 Ph 3	NabiximolsPhase 3 · Multiple SclerosisPartial signal	31 Dec 2026Zanidatamab · Phase 2
Sumitomo Pharma4506 · TSE	8 assets: 3 approved, 2 Ph 3, 2 Ph 2, 1 Ph 1	Droxidopa (Northera)Phase 3 · Parkinson's DiseasePartial signal	20 Oct 2026Ulotaront · Phase 3
Astellas Pharma4503 · TSE	7 assets: 2 approved, 4 Ph 3, 1 Ph 1	RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal	31 Oct 2026Setidegrasib · Phase 1
Azurity PharmaceuticalsPrivate	7 assets: 7 approved	Approved assets only	Sep 2027Zonisamide (Zonisade) · Approved
BeOne MedicinesONC · Nasdaq	7 assets: 2 approved, 2 Ph 3, 1 Ph 2, 2 Ph 1	BGB-11417Phase 3 · Chronic Lymphocytic Leukemia	Nov 2026BGB-11417 · Phase 2
Betta Pharmaceuticals Co.300558 · SZSE ChiNext	7 assets: 3 Ph 3, 2 Ph 2, 2 Ph 1	BPI-16350Phase 3 · HR+/HER2- Metastatic Breast CancerPartial signal	Dec 2026BPI-371153 · Phase 1
Chong Kun Dang Pharmaceutical185750 · KOSPI	7 assets: 2 Ph 3, 2 Ph 2, 3 Ph 1	CKD-701Phase 3 · Age-Related Macular DegenerationReliable signal	16 Nov 2026CKD-706 · Phase 1
Dong-A ST170900 · KOSPI	7 assets: 3 Ph 3, 2 Ph 2, 2 Ph 1	EvogliptinPhase 3 · Type 2 DiabetesReliable signal	Dec 2026DA-2811 · Phase 2
GenmabGMAB · Nasdaq	7 assets: 3 approved, 1 Ph 3, 2 Ph 2, 1 Ph 1	Rina-SPhase 3 · Ovarian Cancer	31 Dec 2026Zenocutuzumab · Phase 2
Shenzhen Salubris Pharmaceuticals002294 · SZSE	7 assets: 3 Ph 3, 4 Ph 2	EnarodustatPhase 3 · Chronic Kidney DiseaseReliable signal	31 Oct 2026JK07 · Phase 2
Sunshine Lake PharmaPrivate	7 assets: 2 Ph 3, 1 Ph 2, 4 Ph 1	Clifutinib BesylatePhase 3 · Acute Myeloid Leukemia	30 Dec 2026HEC169096 · Phase 1/2
Alkermes plcALKS · Nasdaq	6 assets: 5 approved, 1 Ph 3	ALKS 2680Phase 3 · Narcolepsy	Nov 2026ALKS 2680 · Phase 2
Alto NeuroscienceANRO · NYSE	6 assets: 6 Ph 2	ALTO-100Phase 2 · Major Depressive DisorderPartial signal	Dec 2026ALTO-300 · Phase 2
Amneal PharmaceuticalsAMRX · NYSE	6 assets: 6 approved	Approved assets only	None on record
Axsome TherapeuticsAXSM · Nasdaq	6 assets: 3 approved, 2 Ph 3, 1 Ph 2	AXS-14Phase 3 · Fibromyalgia	Dec 2026Solriamfetol · Phase 3
BiohavenBHVN · NYSE	6 assets: 5 Ph 3, 1 Ph 2	BHV-1400Phase 3 · Chronic Kidney Disease	Nov 2026Opakalim · Phase 1
Cheplapharm Arzneimittel GmbHPrivate	6 assets: 6 approved	Approved assets only	None on record
Chiesi FarmaceuticiPrivate	6 assets: 3 approved, 2 Ph 3, 1 Ph 2	Beclomethasone dipropionate/formoterol fumaratePhase 3 · AsthmaReliable signal	Mar 2028metreleptin · Phase 3
IDEAYA BiosciencesIDYA · Nasdaq	6 assets: 1 Ph 3, 1 Ph 2, 4 Ph 1	DarovasertibPhase 3 · Uveal Melanoma	7 Jan 2027IDE397 · Phase 1
Keymed Biosciences2162 · HKEX	6 assets: 3 Ph 3, 2 Ph 2, 1 Ph 1	stapokibartPhase 3 · Atopic DermatitisReliable signal	2 Nov 2026CM512 · Phase 2
Kyowa Kirin4151 · TSE	6 assets: 2 approved, 1 Ph 3, 3 Ph 1	RTA 402Phase 3 · Type 2 DiabetesReliable signal	Dec 2027KK3910 · Phase 1
MacroGenicsMGNX · Nasdaq	6 assets: 1 approved, 1 Ph 2, 4 Ph 1	LorigerlimabPhase 2 · Metastatic Castration-Resistant Prostate Cancer	Nov 2026MGD024 · Phase 1
Neurocrine BiosciencesNBIX · Nasdaq	6 assets: 2 approved, 3 Ph 3, 1 Ph 2	NBI-1117568Phase 3 · SchizophreniaPartial signal	Jul 2027Osavampator · Phase 3
Praxis Precision Medicines, Inc.PRAX · Nasdaq	6 assets: 5 Ph 3, 1 Ph 2	ElsunersenPhase 3 · Epilepsy	Dec 2026Vormatrigine · Phase 3
RemeGen Co., Ltd.688331 · SSE	6 assets: 4 Ph 3, 1 Ph 2, 1 Ph 1	TelitaciceptPhase 3 · Systemic Lupus ErythematosusReliable signal	Dec 2026Disitamab Vedotin · Phase 2/3
Revolution MedicinesRVMD · Nasdaq	6 assets: 1 approved, 1 Ph 3, 2 Ph 2, 2 Ph 1	ZoldonrasibPhase 3 · Non-Small Cell Lung Cancer	31 Dec 2026RMC-9805 · Phase 1
Shanghai Junshi Bioscience1877 · HKEX	6 assets: 1 approved, 1 Ph 3, 3 Ph 2, 1 Ph 1	OngericimabPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal	27 Nov 2026JS207 · Phase 2
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.6990 · HKEX	6 assets: 1 Ph 3, 4 Ph 2, 1 Ph 1	KL-A167Phase 3 · Non-Small Cell Lung Cancer	31 Dec 2026KL590586 · Phase 1/2
XencorXNCR · Nasdaq	6 assets: 2 Ph 2, 4 Ph 1	XmAb5871Phase 2 · Systemic Lupus ErythematosusPartial signal	Feb 2027XmAb819 · Phase 1
ANI Pharmaceuticals, Inc.ANIP · Nasdaq	5 assets: 5 approved	Approved assets only	18 Dec 2029Anastrozole · Phase 3
Ascentage Pharma Group Inc.AAPG ·	5 assets: 2 Ph 3, 1 Ph 2, 2 Ph 1	APG-2575(Lisaftoclax )Phase 3 · Acute Myeloid LeukemiaWeak signal	Dec 2026APG-2575(Lisaftoclax ) · Phase 2
Beijing BiotechPrivate	5 assets: 5 Ph 2	Beijing Biotech anti-CD19 CAR-TPhase 1/2 · Systemic Lupus Erythematosus	14 Feb 2027Dual-target Car-nk Cells · Phase 1/2
CRISPR TherapeuticsCRSP · Nasdaq	5 assets: 1 approved, 3 Ph 2, 1 Ph 1	SRSD107Phase 2 · Atherosclerotic Cardiovascular Disease	Jun 2027CTX310 · Phase 1
Daewoong Pharmaceutical069620 · KOSPI	5 assets: 4 Ph 3, 1 Ph 1	DWP16001Phase 3 · Type 2 DiabetesReliable signal	27 Oct 2026DWRX5003 · Phase 1
Hangzhou Zhongmei Huadong Pharmaceutical000963 · SZSE	5 assets: 3 Ph 3, 1 Ph 1, 1 other	HDG1901Phase 3 · Type 2 DiabetesPartial signal	10 Oct 2026HDM1002 · Phase 3
Hanmi Pharmaceutical128940 · KOSPI	5 assets: 1 Ph 3, 3 Ph 2, 1 other	efpeglenatidePhase 3 · Type 2 DiabetesPartial signal	Jan 2027HM15275 · Phase 2
Iovance BiotherapeuticsIOVA · Nasdaq	5 assets: 2 approved, 3 Ph 2	LN-145Phase 2 · Non-Small Cell Lung CancerWeak signal	Sep 2027IOV-4001 · Phase 1/2
JW Pharmaceutical001060 · KOSPI	5 assets: 4 Ph 3, 1 Ph 2	AnagliptinPhase 3 · Type 2 DiabetesReliable signal	31 Mar 2027Anagliptin · Approved
MedImmune LLCPrivate	5 assets: 3 approved, 2 Ph 3	MonalizumabPhase 3 · Non-Small Cell Lung CancerPartial signal	19 Oct 2026Benralizumab · Approved
Merck KGaAMKKGY · OTC	5 assets: 3 approved, 2 Ph 3	NirogacestatPhase 3 · Multiple Myeloma	28 May 2027Nirogacestat · Phase 2
Mitsubishi Tanabe PharmaPrivate	5 assets: 4 Ph 3, 1 Ph 2	MP-513Phase 3 · Type 2 DiabetesReliable signal	None on record
Ono Pharmaceutical4528 · TSE	5 assets: 3 Ph 2, 2 Ph 1	ONO-1110Phase 2 · Major Depressive DisorderPartial signal	31 Dec 2026ONO-2020 · Phase 2
Rigel PharmaceuticalsRIGL ·	5 assets: 4 approved, 1 Ph 2	R289Phase 1/2 · Myelodysplastic Syndromes	30 Nov 2026Pralsetinib · Phase 2
Sandoz Group AGSDZ · SIX	5 assets: 5 approved	Approved assets only	4 Feb 2027Ranibizumab · Phase 3
Sun Pharmaceutical IndustriesSUNPHARMA · NSE	5 assets: 4 approved, 1 Ph 2	GL0034Phase 2 · Obesity	Apr 2027GL0034 · Phase 2
Tonix PharmaceuticalsTNXP · Nasdaq	5 assets: 3 approved, 2 Ph 2	TNX-1300Phase 2 · Cocaine Intoxication	Feb 2028cyclobenzaprine · Phase 2
Vanda PharmaceuticalsVNDA · Nasdaq	5 assets: 4 approved, 1 Ph 3	tradipitantPhase 3 · Gastroparesis	1 Dec 2026tradipitant · Phase 3
Zealand PharmaZEAL · Nasdaq Copenhagen	5 assets: 3 Ph 3, 1 Ph 2, 1 Ph 1	dasiglucagonPhase 3 · Type 2 DiabetesReliable signal	8 Dec 2026survodutide · Phase 1
A2 Biotherapeutics Inc.Private	4 assets: 4 Ph 2	A2B395Phase 1/2 · Non-Small Cell Lung Cancer	Dec 2026A2B530 · Phase 1/2